- Home
- BROS vs BBIO Comparison
BROS vs BBIO Comparison
Compare BROS & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BROS
- BBIO
- Stock Information
- Founded
- BROS 1992
- BBIO 2015
- Country
- BROS United States
- BBIO United States
- Employees
- BROS N/A
- BBIO N/A
- Industry
- BROS Restaurants
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- BROS Consumer Discretionary
- BBIO Health Care
- Exchange
- BROS Nasdaq
- BBIO Nasdaq
- Market Cap
- BROS 9.4B
- BBIO 7.6B
- IPO Year
- BROS 2021
- BBIO 2019
- Fundamental
- Price
- BROS $67.59
- BBIO $41.73
- Analyst Decision
- BROS Strong Buy
- BBIO Strong Buy
- Analyst Count
- BROS 15
- BBIO 13
- Target Price
- BROS $78.27
- BBIO $56.67
- AVG Volume (30 Days)
- BROS 2.7M
- BBIO 2.5M
- Earning Date
- BROS 08-06-2025
- BBIO 07-31-2025
- Dividend Yield
- BROS N/A
- BBIO N/A
- EPS Growth
- BROS 109.32
- BBIO N/A
- EPS
- BROS 0.38
- BBIO N/A
- Revenue
- BROS $1,361,068,000.00
- BBIO $127,415,000.00
- Revenue This Year
- BROS $26.23
- BBIO $102.05
- Revenue Next Year
- BROS $24.18
- BBIO $54.69
- P/E Ratio
- BROS $176.01
- BBIO N/A
- Revenue Growth
- BROS 30.42
- BBIO N/A
- 52 Week Low
- BROS $26.96
- BBIO $21.62
- 52 Week High
- BROS $86.88
- BBIO $41.90
- Technical
- Relative Strength Index (RSI)
- BROS 46.23
- BBIO 69.82
- Support Level
- BROS $65.75
- BBIO $39.65
- Resistance Level
- BROS $71.38
- BBIO $41.36
- Average True Range (ATR)
- BROS 2.99
- BBIO 1.51
- MACD
- BROS -0.71
- BBIO 0.35
- Stochastic Oscillator
- BROS 15.17
- BBIO 97.37
About BROS Dutch Bros Inc.
Dutch Bros Inc is an operator and franchisor of drive-thru coffee shops that are focused on serving hand-crafted beverages. The company's hand-crafted beverage-focused lineup features hot and cold espresso-based beverages, cold brew coffee products, proprietary energy drinks, tea, lemonade, smoothies and other beverages. The company has two reportable operating segments Company-operated shops and Franchising. It derives maximum revenue from Company operated shops.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.